← Leaderboards
Olga V Razorenova
University Of California-Irvine
$596,198
Attributed
$596,198
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $209.6K · FY2016–25$250K$187.5K$125K$62.5K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$596,198 · 3
By mechanism
R21$382,594 · 1
R03$141,777 · 1
P20$71,827 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California-Irvine
Same institution · by research overlap
- Michael Demetriou$19,395,048
- Mei Kong$7,199,338
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsGenesMutationAffectNeoplasm MetastasisCancer CellTumorMalignant NeoplasmsNormal Tissue MorphologyNormal CellProteinsNeoplastic CellIn VivoNovel TherapeuticsIn VitroMediatingHypoxia Inducible FactorHypoxia Inducible Factor 1CellsCancer TherapyCessation Of LifeLungMouse ModelPrimary Neoplasm
Grant awards (5)
Therapeutic targeting of VHL-deficient clear cell renal cell carcinoma$209,646
R21 · FY2025 · CA · contact PI
Therapeutic targeting of VHL-deficient clear cell renal cell carcinoma$172,948
R21 · FY2024 · CA · contact PI
Racial disparity in triple-negative breast cancer lipid metabolism$71,827
P20 · FY2021 · CA · contact PI
Synthetic lethality in VHL tumor suppressor null tumors$70,703
R03 · FY2017 · CA · contact PI
Synthetic lethality in VHL tumor suppressor null tumors$71,074
R03 · FY2016 · CA · contact PI